While the broader market has struggled with the S&P 500 down 5.5% since October 2025, Sealed Air has surged ahead as its stock price has climbed by 18.2% to $42.05 per share. This was partly due to its solid quarterly results, and the performance may have

WESCO currently trades at $274.20 and has been a dream stock for shareholders. It’s returned 215% since April 2021, blowing past the S&P 500’s 57.8% gain. The company has also beaten the index over the past six months as its stock price is up 28.9%.

Beyond Meat's latest quarterly report shows the business is still struggling.

Akamai Technologies has been on fire lately. In the past six months alone, the company’s stock price has rocketed 51.4%, reaching $114.84 per share. This performance may have investors wondering how to approach the situation.

Consistent double-digit returns could make investors very wealthy over a couple of decades.

Asana has gotten torched over the last six months - since October 2025, its stock price has dropped 51.3% to $6.47 per share. This might have investors contemplating their next move.

Nike's latest quarterly report arrived with some bad news for investors.

MYR Group currently trades at $282.13 and has been a dream stock for shareholders. It’s returned 283% since April 2021, blowing past the S&P 500’s 57.8% gain. The company has also beaten the index over the past six months as its stock price is up 39.7% th

When companies beat revenue and earnings expectations as much as Micron Technologies did in its most recent quarter, the market often heaps on praise for stellar results. Not this time, though.

Expectations are running high ahead of the gold miner's upcoming earnings report.

The Schwab U.S. Dividend Equity ETF is increasing its allocation to consumer staples stocks.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Methode Electronics (NYSE:MEI) and its peers.

Eil Lilly shares popped after the FDA approved a new GLP-1 weight-loss pill from the pharmaceutical giant.

The financial services giant is still sensitive to interest rate swings.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Enpro (NYSE:NPO) and its peers.